ABSTRACT Brucella abortus, the bacterial agent of the worldwide zoonosis brucellosis, primarily infects host phagocytes, where it undergoes an intracellular cycle within a dedicated membrane-bound vacuole, the Brucella-containing vacuole (BCV). Initially of endosomal origin (eBCV), BCVs are remodeled into replication-permissive organelles (rBCV) derived from the host endoplasmic reticulum, a process that requires modulation of host secretory functions via delivery of effector proteins by the Brucella VirB type IV secretion system (T4SS). Following replication, rBCVs are converted into autophagic vacuoles (aBCVs) that facilitate bacterial egress and subsequent infections, arguing that the bacterium sequentially manipulates multiple cellular pathways to complete its cycle. The VirB T4SS is essential for rBCV biogenesis, as VirB-deficient mutants are stalled in eBCVs and cannot mediate rBCV biogenesis. This has precluded analysis of whether the VirB apparatus also drives subsequent stages of the Brucella intracellular cycle. To address this issue, we have generated a B. abortus strain in which VirB T4SS function is conditionally controlled via anhydrotetracycline (ATc)-dependent complementation of a deletion of the virB11 gene encoding the VirB11 ATPase. We show in murine bone marrow-derived macrophages (BMMs) that early VirB production is essential for optimal rBCV biogenesis and bacterial replication. Transient expression of virB11 prior to infection was sufficient to mediate normal rBCV biogenesis and bacterial replication but led to T4SS inactivation and decreased aBCV formation and bacterial release, indicating that these postreplication stages are also T4SS dependent. Hence, our findings support the hypothesis of additional, postreplication roles of type IV secretion in the Brucella intracellular cycle. IMPORTANCE Many intracellular bacterial pathogens encode specialized secretion systems that deliver effector proteins into host cells to mediate the multiple stages of their intracellular cycles. Because these intracellular events occur sequentially, classical genetic approaches cannot address the late roles that these apparatuses play, as secretion-deficient mutants cannot proceed past their initial defect. Here we have designed a functionally controllable VirB type IV secretion system (T4SS) in the bacterial pathogen Brucella abortus to decipher its temporal requirements during the bacterium's intracellular cycle in macrophages. By controlling production of the VirB11 ATPase, which energizes the T4SS, we show not only that this apparatus is required early to generate the Brucella replicative organelle but also that it contributes to completion of the bacterium's cycle and bacterial egress. Our findings expand upon the pathogenic functions of the Brucella VirB T4SS and illustrate targeting of secretion ATPases as a useful strategy to manipulate the activity of bacterial secretion systems. 
BCV (eBCV) (10) (11) (12) . eBCVs feature an acidic pH and hydrolytic activity and accumulate late endocytic/lysosomal markers on their vacuolar membrane, such as lysosome-associated membrane protein 1 (LAMP1), indicative of a lysosomal nature (13, 14) . eBCVs then interact with endoplasmic reticulum (ER) exit sites (ERES) along the host early secretory pathway and are progressively remodeled into replication-permissive vacuoles (rBCVs) derived from, and with functional properties of, the ER (10, 11, 15) , where Brucella undergoes replication. Subsequent to bacterial proliferation, rBCVs are engulfed into autophagosome-like structures to become autophagic BCVs (aBCVs), a final stage that facilitates completion of the bacterium's intracellular cycle by promoting bacterial egress (12) . Brucella therefore displays a multistage intracellular cycle, which illustrates the complexity of its interactions with host cellular pathways and suggests that the bacterium actively controls these sequential intracellular events.
Remodeling of eBCV to rBCV requires functions of the Brucella VirB type IV secretion system (T4SS), a protein translocation apparatus essential for intracellular replication, modulation of host immune functions, and establishment of chronic brucellosis (7, 16) , as mutants of various virB genes encoding T4SS components are defective in rBCV biogenesis and replication (2, 10, 17) , stalling in eBCVs, where they are eventually killed (10) . While the dependence of rBCV biogenesis on VirB argues that this stage of the Brucella intracellular cycle is mediated by the action of bacterially delivered effectors, it is unknown whether replication in rBCV and postreplication stages, such as aBCV formation and bacterial egress, are VirB dependent. Since VirB-deficient strains of Brucella do not reach the replicative rBCV stage, genetic inactivation of the VirB apparatus cannot be used to examine whether any stage post-rBCV biogenesis is a VirB T4SS-dependent process. We reasoned that temporal control of VirB functionality during the bacterium's intracellular cycle may address these issues. Here we have designed and generated strains of Brucella abortus in which expression of an essential virB gene depends upon the presence of the inducer anhydrotetracycline (ATc) and can be induced or repressed in a temporal manner to control functionality of the VirB T4SS. Applying this approach to the VirB11 ATPase, we show that VirB T4SS expression within the eBCV is required early for optimal rBCV biogenesis and is also necessary for aBCV formation and bacterial egress, therefore uncovering novel roles of this secretion machinery in postreplication stages of the Brucella intracellular cycle.
RESULTS
Inactivation and conditional complementation of the B. abortus VirB11 ATPase. To assess the role of the VirB T4SS in postreplication stages of the Brucella intracellular cycle, we reasoned that enabling VirB T4SS activity to allow rBCV biogenesis and then disabling its function to test its role in bacterial replication within rBCVs, aBCV formation, and bacterial egress would circumvent the early trafficking blockage that characterizes constitutively defective virB mutant strains in which single or multiple virB genes are inactivated (2, 10, 15, 18) . We therefore sought to generate a B. abortus strain in which VirB T4SS activity is conditional by constructing an in-frame deletion mutant in an essential virB gene and complementing it with a conditionally expressed, single chromosomal copy inserted at a secondary locus. The Brucella VirB T4SS is composed of 11 VirB subunits (VirB1 to VirB11). On the basis of their homology with other closely related P-type VirB T4SSs, such as those of Agrobacterium tumefaciens or the IncW conjugative plasmid R388, VirB2, VirB3, VirB5, VirB6, VirB7, VirB8, VirB9, and VirB10 subunits likely play structural roles (19) , while VirB4 and VirB11 are secretion ATPases that energize the system for T4SS assembly and effector translocation (19) . We chose to target the VirB11 ATPase, based on (i) the location of virB11 as the last gene of the virB operon, to avoid polar effects of its deletion; (ii) its demonstrated role in VirB T4SS-dependent functions (2); and (iii) its turnover being potentially faster than that of VirB structural components, as an inner membraneassociated ATPase (19) . We first generated an in-frame deletion of codons 6 to 356 of virB11 via SacB-assisted allelic replacement (15) to generate B. abortus 2308⌬virB11. We then constructed a derivative of a Brucella-adapted mini Tn7 transposon (20) carrying two different cistrons (Fig. 1A) : the hemagglutinin (HA)-tagged virB11 gene under the control of the tetR-P tetA region of Tn10 to synthesize HA-VirB11 in an anhydrotetracycline (ATc)-dependent manner and an artificial dsRed m -aphA3 bicistronic operon under the control of the constitutive P aphA3 promoter for kanamycin selection and fluorescence microscopy purposes. The resulting transposon, mTn7K-tetRA-virB11 (Fig. 1A) , was inserted at the single att Tn7 locus downstream of glmS in B. abortus 2308⌬virB11 to generate the VirB conditional strain 2308⌬virB11::virB11i. The same transposon was also inserted into the wild-type strain to generate B. abortus 2308::virB11i and to test for any deleterious effect of a second chromosomal copy of virB11. ATc control of VirB11 production in strain 2308⌬virB11::virB11i was first tested in tryptic soy broth (TSB), and the results showed no detectable production of VirB11 in the absence of ATc and clear induction after 4 h of treatment with ATc (100 ng/ml) (Fig. 1B, left panel) , indicating that VirB11 production is controllable by ATc. We then tested the intracellular behavior of both strain 2308::virB11i and strain 2308⌬virB11::virB11i in murine bone marrow-derived macrophages (BMMs) in the presence and absence of ATc. Intracellular growth of strain 2308::virB11i showed a typical intracellular growth pattern regardless of the presence or absence of ATc, with an increase in recoverable bacterial numbers after 12 h pi (Fig. 1C) , indicating that the presence of the inducible chromosomal copy of virB11 does not affect Brucella intracellular growth. In the absence of ATc, the 2308⌬virB11:: virB11i strain showed the defective intracellular growth typical of a VirB-deficient mutant (2, 10, 15) , indicating tight repression of VirB11 production by the tetR-P tetA region. In contrast, addition of ATc at the time of infection restored intracellular growth of the VirB conditional strain to wild-type levels, demonstrating full complementation of the virB11 deletion by the ATc-inducible copy of virB11. Under these experimental conditions, VirB11 was detected by Western blotting as early as 1 h postinfection (pi) and throughout a 48 h time course during which ATc treatment was maintained (Fig. 1B, right panels) , increasing with bacterial replication past 12 h pi. This demonstrated that VirB11 synthesis in strain 2308⌬virB11::virB11i is maintained by prolonged ATc induction. Consistent with intracellular growth, monitoring BCV intracellular trafficking during the first 24 h pi through acquisition (eBCV stage) and then exclusion (rBCV stage) of lysosomal membrane marker LAMP1 on BCV membranes (13) showed a drastic defect in rBCV biogenesis in the 2308⌬virB11::virB11i strain in the absence of ATc, in agreement with a VirB functional defect, which was fully complemented upon ATc addition (Fig. 1D) . Confocal microscopy analysis of infected BMMs at 24 h pi confirmed that Smith et al.
ATc-treated BMMs infected with strain 2308⌬virB11::virB11i harbored replicating intracellular bacteria within LAMP1-negative rBCVs at levels similar to those seen with the ATc-treated or untreated 2308::virB11i control strain, while strain 2308⌬virB11:: virB11i did not show any replication pattern and was restricted to LAMP1-positive eBCVs in the absence of ATc (Fig. 1E) , as expected of VirB-deficient bacteria. Taken together, these results establish that we have generated a B. abortus strain in which VirB functionality can be tightly controlled intracellularly using ATc, allowing us to switch from VirB-deficient to VirB-competent bacteria.
VirB T4SS function is required early during infection for optimal intracellular replication. On the basis of the characterization presented above, we first sought to determine the temporal requirements of VirB functions during the Brucella intracellular cycle. Early defects of VirB-deficient mutants, which are restricted to eBCVs (2, 10) , and previous analysis of intracellular virB gene expression argue for a rapid induction of the VirB T4SS (13, 21, 22) , suggesting that its activity is required early during the bacterium's intracellular cycle. Yet this assumption has not been formally demonstrated. We first examined intracellular expression of the virB operon under our experimental conditions in wild-type B. abortus 2308 via quantitative PCR (qPCR) using either virB4 or virB11 mRNAs and confirmed very strong induction upon bacterial uptake by BMMs which peaked at 4 h pi (~150-fold for virB4; 12-fold for virB11) and decreased thereafter ( Fig. 2A) , consistent with previous reports (13, 21, 22) . To determine VirB T4SS functional requirements at these time points, we infected BMMs with strain 2308⌬virB11::virB11i and induced VirB activity with sequential delays postinfection to monitor bacterial growth over time. Compared to ATc induction at the time of infection (0 h pi), induction at 2 h pi did not significantly affect bacterial replication (Fig. 2B) . In contrast, ATc addition at either 4 or 6 h pi decreased bacterial replication at 24 h pi by nearly 1 order of magnitude (Fig. 2B) . Moreover, ATc addition at 8 h pi decreased replication by 2 orders of magnitude, yielding no net increase in bacterial numbers by 24 h pi (Fig. 2B) . ATc addition at 12 h pi failed to mediate any growth of strain 2308⌬virB11::virB11i, which behaved similarly to the non-ATc-induced, VirB-deficient bacteria at 24 h pi (no ATc; Fig. 2B ). While bacteria treated with ATc from 0 to 6 h pi sustained similar growth after 24 h pi, those treated at either 8 or 12 h pi underwent substantial replication between 24 and 48 h pi (Fig. 2B ) and yet did not reach control levels (ATc; 0 h pi), indicating that the growth defects seen at 24 h pi upon delayed VirB induction were recoverable. Of note, minor bacterial growth was observed between 24 and 48 h pi in the absence of ATc induc- tion (no ATc), which reflected limited replication in a few BMMs (data not shown), possibly due to leaky virB11 expression in these bacteria. Altogether, this demonstrates that the Brucella VirB T4SS is functionally required early during the bacterium's intracellular cycle, consistent with its intracellular expression pattern, and that its function needs temporal coordination with the stage of conversion of eBCV to rBCV to mediate optimal initiation of intracellular growth.
Minimal induction of VirB11 required for rBCV biogenesis and replication. On the basis of the effective control of VirB T4SS activity through conditional production of VirB11, in order to examine potential roles of the VirB T4SS in postreplication stages of the Brucella intracellular cycle, we next sought to determine whether this system is amenable to inactivation once the VirB T4SS has been induced. We reasoned that inactivation of the VirB T4SS requires turnover of HA-VirB11 sufficient to render the T4SS inactive and therefore first examined HA-VirB11 stability upon ATc removal. Following a 4-h induction with ATc in TSB, ATc washout, and addition of chloramphenicol (Cm; 10 g/ ml) to inhibit de novo protein synthesis, HA-VirB11 displayed a progressive decrease within a 60-min time course analysis, with a calculated half-life (t 1/2 ) of 16.1 min (Fig. 3A) , indicating a significant instability of the protein. Upon infection of BMMs with strain 2308⌬virB11::virB11i and ATc induction for 6 h, however, HA-VirB11 displayed a longer half life (t 1/2 ϭ 79.8 min; Fig. 3B ), reflecting increased stability in intracellular bacteria. Yet these results suggested that the turnover of HA-VirB11 that occurred was sufficient to inactivate VirB T4SS-dependent functions past 24 h pi. On the basis of these results, we aimed to define the minimal induction conditions that would mediate rBCV biogenesis and Brucella replication by 24 h pi and yet lead rapidly thereafter to VirB T4SS inactivation via HA-VirB11 turnover. We therefore compared the levels of bacterial replication of strain 2308⌬virB11::virB11i in BMMs that occurred upon ATc treatment at 24 h (ATc 24h ), 12 h (ATc 12h ), and 4 h (ATc 4h ) pi and 4 h prior to infection (ATc Ϫ4h ). Surprisingly, all treatments supported comparable growth levels by 24 h pi (Fig. 4A ), indicating that a short (4 h) period of induction in bacterial culture prior to infection (ATc preinduction) was sufficient to provide strain 2308⌬virB11::virB11i with the VirB-dependent functions neces- sary to generate rBCVs and initiate replication. To confirm these results, we compared levels of rBCV biogenesis and bacterial growth of strain 2308⌬virB11::virB11i under conditions of either sustained ATc treatment (ATc 24h ) or 4 h treatment prior to infection (ATc Ϫ4h ). Compared to the results seen in the absence of ATc induction, ATc preinduction was sufficient to restore rBCV biogenesis and bacterial replication to the levels seen with the sustained induction at up to 72 h pi ( Fig. 4B and C) . Importantly, HA-VirB11 was detectable by Western blotting at 4 h pi under all conditions but not by 24 h pi upon ATc preinduction (Fig. 4A) . This indicates that ATc preinduction led to significant HA-VirB11 turnover by the time bacteria replicated in rBCVs, suggesting VirB T4SS inactivation by this stage. Further examination of intracellular HA-VirB11 turnover in BMMs upon 4 h of ATc preinduction showed it was no longer detectable after 12 h pi (Fig. 4D) , further suggesting that these experimental conditions are amenable to the analysis of the role of the VirB T4SS in postreplication stages. To confirm this, we evaluated VirB T4SS functionality by measuring accumulated delivery of known Brucella effectors, BspD and BspI (20, 23) , into J774A.1 macrophages via a TEM1 ␤-lactamase translocation assay. Compared to TEM1 fusion to a B. abortus protein (encoded by the BAB2_0654 locus) that is not translocated upon infection (20) , at 16 h pi, BspD and BspI showed significant and comparable levels of translocation from strain 2308⌬virB11::virB11i bacteria treated with ATc either for the whole infection time (ATc 16h ) or for a 4 h preinduction (ATc Ϫ4h ) (Fig. 4E) . This argues for the occurrence of similar levels of VirB T4SS activity under the two sets of ATc conditions at this time point. While accumulation of translocated BspD and BspI in J774A.1 cells between 16 and 24 h pi upon sustained ATc treatment (ATc 16/24h ) was detectable via an increase in the percentage of cells where CCF2-AM conversion occurred, their delivery by 2308⌬virB11::virB11i bacteria subjected to the 4 h preinduction (ATc Ϫ4h ) was stalled between these time points (Fig. 4E) , indicating a loss of VirB T4SS activity between 16 and 24 h pi that is consistent with the decay of HA-VirB11 observed under the same experimental conditions (Fig. 4D ). These differences in T4SS effector delivery did not result from differences in viable intracellular bacteria, as the two ATc treatments yielded comparable intracellular CFU levels during the time frame of analysis (Fig. 4C ). This demonstrates a strongly reduced function of the VirB T4SS during the bacterial replication phase in rBCVs under conditions of minimal induction of HA-VirB11 prior to infection. Taken together, these results established experimental conditions that allow (i) VirB-dependent early stages of the Brucella intracellular cycle to proceed and (ii) subsequent reduction of VirB T4SS activity, thus permitting analysis of its role in Brucella postreplication stages.
Inactivation of the VirB T4SS postreplication impairs aBCV formation and bacterial release. Subsequent to VirB T4SS-dependent rBCV biogenesis, Brucella undergoes replication that is followed by rBCV remodeling into aBCVs (24 to 72 h pi), a process that facilitates bacterial egress (12) . Whether replication, aBCV formation, and bacterial egress are VirB-dependent processes is unknown. On the basis of the detection of reduced VirB activity by 24 h pi following the 4 h ATc preinduction treatment ( Fig. 4) , we first sought to test whether Brucella intracellular growth was affected between 24 and 72 h pi in BMMs. Compared to sustained ATc treatment, early transient activation of the VirB T4SS did not affect Brucella replication (Fig. 4C) , indicating either that a functional T4SS is dispensable for growth within rBCVs or that its functional requirements are established prior to 24 h pi and sustained over time. In contrast, formation of aBCVs was significantly reduced (28.8% Ϯ 2.5% of infected BMMs under conditions of sustained activation compared to 15.1% Ϯ 2.4% under conditions of transient activation, P ϭ 0.0024 [t test]; Fig. 5A and B) . Bacterial egress was then assessed by adding a secondary population of Cell Tracker Green-labeled BMMs to the originally infected, unlabeled BMMs and by measuring their infection between 48 and 72 h pi upon removal of gentamicin. The percentage of newly infected, Cell Tracker Green-positive BMMs was dramatically decreased upon inactivation of the VirB T4SS (34.5% under conditions of sustained activation compared to 5.5% under conditions of transient activation; Fig. 5C and D) to the level seen with sustained treatment with gentamicin ( Fig. 5C ; see also Fig. S1 in the supplemental material), which blocked reinfection events (12) . Considering that aBCVs facilitate Brucella release from macrophages (12) , these findings clearly demonstrate that aBCV formation and subsequent bacterial egress are VirB T4SS-dependent processes.
DISCUSSION
Secretion systems encoded by intracellular bacteria deliver arrays of effectors that modulate host cell processes involved in multiple stages of their intracellular cycles, including invasion, modulation of phagosome maturation, inhibition of innate immune responses, biogenesis of replicative organelles, and bacterial egress. Because these intracellular events occur sequentially, classical genetic, mutant-based approaches have failed to address the roles that secretion systems play in later stages, as secretion-deficient mutants cannot proceed past their initial defect. Brucella spp. undergo a complex intracellular cycle in phagocytes which invokes the sequential modulation of host endocytic, secretory, and autophagic machineries (16) . While the role of the VirB T4SS in rBCV biogenesis has been clearly established via the use of VirBdefective mutants (2, 10, 15) , its temporal requirements and roles in postreplication stages eluded examination until the functionality of the VirB T4SS apparatus could be temporally controlled.
A few studies have previously used postentry inactivation approaches with other pathogens. Arabinose-inducible control of the Shigella flexnerii Mxi-Spa type III secretion system gene icsA has revealed a postinvasion role of the S. flexnerii Mxi-Spa type III secretion system in the bacterium's intercellular spread (5) . Inducible control of Cre recombinase-mediated deletion of Legionella pneumophila Dot/Icm T4SS gene icmQ, and of T4SS effector sdhA, has highlighted their roles in intracellular bacterial replication (6) . Previous evidence has, however, suggested that T4SSs may remain stable once assembled and active even after downregulation of their expression (6, 24) , questioning the possibility of controllable inactivation of a T4SS. In our attempt to modulate the activity of the VirB T4SS by controlling production of an essential VirB component, we chose to target the VirB11 ATPase, given its predicted peripheral association with the apparatus at the inner membrane (19) and its role in providing energy for T4SS effector translocation. As such, we reasoned that depletion of VirB11 would inactivate the VirB T4SS, even if structural VirB components are stably assembled, a scenario supported by the previous demonstration that loss of VirB11 production via deletion of the virB11 gene does not affect production or stability of other VirB components (17) . Complementation of a virB11 inframe deletion with an ATc-controllable chromosomal copy of virB11 showed tight control of VirB11 synthesis in the absence of induction and full conditional complementation of the mutant. Such tight transcriptional control was important to clearly demonstrate the temporal requirements of VirB T4SS activity during conversion of eBCV to rBCV, without which bacteria displayed protracted growth, even after ATc-mediated induction of VirB11. This temporal coordination for VirB T4SS requirements is consistent with the natural expression pattern of the virB operon (13, 21) , whose expression is rapidly induced in eBCVs, peaks during rBCV biogenesis, and progressively decreases at the onset of bacterial replication. While such an expression pattern may indicate a requirement of the T4SS only at early stages, it may also reflect rapid production as well as assembly that is prolonged over time to fulfill additional functions at later stages of the bacterium's cycle.
Assessing late roles of the VirB T4SS requires early activation of the VirB T4SS to allow rBCV biogenesis and the onset of bacterial replication, followed by a rapid turnover of VirB11 upon repression of its production. While HA-tagged VirB11 showed rapid turnover in broth culture, the rate was considerably lower in intracellular bacteria. The cause of the observed differences in the levels of VirB11 stability under broth and intracellular conditions is unclear, but the differences could either result from the experimental conditions or be biologically relevant: The efficiency of intracellular TetR-mediated repression of virB11 expression may not have been as high as that seen in broth, due to a longer persistence of ATc in intracellular bacteria after washout that would have prolonged VirB11 synthesis. Yet this should not have affected the outcome of chloramphenicol chase experiments, where de novo protein synthesis is blocked. Hence, we favor a biological explanation, where the VirB11 ATPase is stabilized when engaged in an actively translocating T4SS in intracellular bacteria compared to broth culture conditions where VirB components are produced but may not be assembled or engaged in effector translocation. Future studies are needed to address this issue. Regardless of the increased stability of VirB11 in mammalian cells, its intracellular turnover was sufficient to abolish its detectable expression between 12 and 24 h pi upon a short period of ATc induction prior to infection, consistent with its dilution during the bacterial division initiated between these time points. Loss of VirB11 production in intracellular bacteria was corroborated by a block in accumulation of effector translocation between 16 and 24 h pi, arguing for VirB T4SS inactivation during the early stages of bacterial replication. On the basis of these results, we did not see any defect in further bacterial replication between 24 and 72 h pi, suggesting that the VirB T4SS is not required for bacterial growth once bacteria have established their rBCV. However, we cannot exclude the possibility that some VirB effectors are required for bacterial growth within rBCVs but were delivered prior to VirB inactivation under our experimental conditions, i.e., before 24 h pi, and remained active afterward. Hence, future studies will aim to destabilize VirB11 more via targeting it to protease degradation (25) in order to inactivate the VirB T4SS earlier during the bacterium's intracellular cycle.
The strongly reduced VirB T4SS activity observed by 24 h pi under our experimental conditions gave us the opportunity to evaluate the role of this secretion system in aBCV formation and bacterial egress, events which occur between 48 and 72 h pi (12) . Bacteria displaying a loss of VirB T4SS activity by 24 h pi were significantly affected in their ability to remodel rBCVs into aBCVs, despite normal bacterial growth at these time points, and failed to undergo bacterial egress. These results clearly demonstrate a role of VirB type IV secretion in these late events of the Brucella intracellular cycle and argue that aBCV formation and bacterial egress are controlled by VirB T4SS effectors. aBCV formation requires a subset of host machineries involved in autophagy (12) , suggesting that specific VirB T4SS effectors modulate this pathway to promote aBCV formation. Given the autophagic nature of these late vacuoles and their role in bacterial egress, it is also tempting to speculate that bacterial release via these organelles may invoke processes related to secretory autophagy which might be uncovered by identification of the VirB T4SS effectors controlling these processes.
MATERIAL AND METHODS
Bacterial strains and culture. Wild-type Brucella abortus strain 2308 and its derivatives were grown on tryptic soy agar (TSA) (Difco) for 72 h at 37°C and subsequently in tryptic soy broth (TSB; Difco) at 37°C with shaking to an optical density at 600 nm (OD 600 ) of~1.0. When indicated, bacterial cultures were treated with 100 ng/ml of anhydrotetracycline (ATc; Acros Organics) 4 h prior to infection. All experiments performed with B. abortus strains, including the use of an ATc-inducible gene expression system which does not confer resistance to tetracycline, were carried out in a biosafety level 3 facility according to standard operating procedures approved by Washington State University Institutional Biosafety Committee and in compliance with NIH guidelines and CDC Division of Select Agents and Toxins regulations.
Construction of B. abortus strain 2308⌬virB11::virB11i. To generate a B. abortus strain in which the functionality of the VirB T4SS is controllable by the inducer ATc, we first deleted virB11 within the virB chromosomal locus as follows: two DNA hemifragments flanking virB11 were PCR amplified using either primers RC179 (5=-CGGTACCCGGGGATC CGAGAACCTGCAATGACACAG-3=) and RC180 (5=-GTCACTTCGGT TTGACATCAT-3=), or primers RC181 (5=-GTCAAACCGAAGTGACTG AAGCTGCAACTTTCACCC-3=) and RC182 (5=-ATGCCTGCAGGTCG ACGCCAGTTGAAATAATCGTCGC-3=). The two hemifragments were fused via overlap extension PCR to generate a ⌬virB11 fragment containing an in-frame deletion of VirB11 codons 6 to 356 while preserving the integrity of overlapping virB10 and were cloned into the sacB-assisted pJC80 allelic replacement plasmid (15) using BamHI and SalI restriction sites to yield pJC80⌬virB11. pJC80⌬virB11 was electroporated into wildtype B. abortus strain 2308, and merodiploids were selected for resistance to carbenicillin and sucrose sensitivity and subjected to sucrose selection, as previously described (15) . virB11 deletion at the correct chromosomal locus in B. abortus 2308⌬virB11 was confirmed by PCR using primers RC189 (5=-GACGGAACCACAGTGCCAG-3=) and RC190 (5=-CGCCGA TCATAACGACAAC-3=). To generate the complementing transposon mini-Tn7K⍀tetRA-HA-virB11, we first constructed the artificial bicistronic operon P aphA3 -dsred m -aphA3 by amplifying (i) the 1,050-bp P aphA3 -dsRed m fragment from pJC44(13) using primers TW563 (5=-CAA CTGCAGCCAGCGAACCATTTGAGG-3=) and TW575 (5=-TGCGAAA CGATCCTCTATCGCGGCCGCTCTACTGG-3=) and (ii) the 800-bp aphA3 gene from pBBR1MCS-2 using primers TW568 (5=-AGGATCGT TTCGCATGATTG-3=) and TW569 (5=-GCGGGATCCTCAGAAGAAC TCGTCAAGAAG-3=). These fragments were then fused via overlap extension PCR using primers TW563 and TW569 and then cloned into pCR2.1TOPO (Thermo Fisher Scientific) according to the manufacturer's instructions. The 1,850-bp P aphA3 -dsred m -aphA3 fragment was sequenced, verified, and then amplified using primers TW600 (5=-CTTCT CGAGGAATTCCCAGCGAACCATTTGAGG-3=) and TW598 (5=-CTC ACTAGTGGATCCTCAGAAGAACTCGTCAAGAAG-3=) and cloned into pUC18T-miniTn7 (26) using an In-Fusion cloning kit (Clontech) to generate pUC18T-miniTn7K-dsRed. Separately, a 1,107-bp virB11 fragment was amplified from B. abortus 2308 genomic DNA (gDNA), subjected to HA tagging at its 5= end using primers RC203 (5=-ATGTATCC ATATGATGTTCCAGATTATGCTATGTCAAACCGAAGTGAC-3=) and RC164 (5=-GCCCAAGCTTCTCGAGTCATTGCGTCTTCTCACTGTG-3=), and fused via overlap extension PCR to a 705-bp tetR-P tetA fragment amplified from Tn10 using primers TW75 (5=-TAGAACTAGTGGATCCTT AAGACCCACTTTCACA-3=) and TW76 (5=-TTCACTTTTCTCTATCA CTG-3=). The resulting 1,812-bp tetR-P tetA -HA-virB11 fragment, initially cloned into pBBR1MCS-2 BamHI-SalI restriction sites, was further PCR amplified using primers RC163 (5=-GGTTCGCTGGGAATTCTTAAGA CCCACTTTCACA-3=) and RC164 (5=-GCCCAAGCTTCTCGAGTCAT TGCGTCTTCTCACTGTG-3=) and cloned as an EcoRI-XhoI fragment into pUC18T-miniTn7K-dsRed to generate pUC18T-miniTn7K-dsRed⍀tetRA-HA-virB11 (Fig. 1A) , which was verified by sequencing. miniTn7K-dsRed⍀tetRA-HA-virB11 was then inserted at the att Tn7 locus in either B. abortus 2308⌬virB11 or B. abortus 2308 via electroporation of its delivery plasmid and the helper plasmid pUC18T-Tn7-tnp, as previously described (20) , to generate strain 2308⌬virB11::virB11 i or strain 2308::virB11i, respectively, and the results were confirmed by PCR amplification of the transposon insertion locus.
Mammalian cell culture and infection. Murine bone marrowderived macrophages (BMMs) were generated from bone marrow of female C57BL/6J mice (Envigo) (6 to 12 weeks old) and cultured in Dulbecco's modified Eagle's medium (DMEM; Corning) (1 g/liter glucose) supplemented with 10% fetal bovine serum (FBS; Life Technologies, Inc.) and 10% L-929 mouse fibroblast-conditioned medium at 37°C in 10% CO 2 , as previously described (13) . Two days prior to infection, BMMs were seeded at 5 ϫ 10 4 (24-well plates) cells/well or 1 ϫ 10 6 (6-well plate) cells/well and then infected with B. abortus strains at the desired multiplicity of infection (MOI) via a 10-min centrifugation at 400 ϫ g and 4°C to synchronize infection. Following 20 min of incubation at 37°C in 10% CO 2 , BMMs were washed five times with 37°C DMEM to remove extracellular bacteria and replenished with complete medium, and medium supplemented with 100 g/ml gentamicin (Gibco) was added between 1 and 2 h postinfection to kill the remaining extracellular Brucella cells. Afterward, the culture medium was replaced every 24 h during infection. When indicated, 100 ng/ml ATc (Acros Organics) was added to the culture medium for the specified times postinfection.
Immunofluorescence microscopy. BMMs were seeded at 5 ϫ 10 4 cells/well on 12-mm-diameter glass coverslips in 24-well plates and infected with DsRed m -producing B. abortus strains at an MOI of 10. At specified time points, coverslips were washed three times in 1ϫ phosphate-buffered saline (PBS) and fixed using 3% paraformaldehyde-PBS (pH 7.4) at 37°C for 20 min. Immunostaining was carried out as described previously (13) using rat anti-mouse LAMP1 antibody (clone 1D4B; developed by J. T. August and obtained from the Developmental Studies Hybridoma Bank [DSHB] developed under the auspices of the National Institute of Child Health and Human Development [NICHD] and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA) (1:500 dilution) followed by either Alexa Fluor 488-conjugated donkey anti-rat secondary antibody (Invitrogen) (1:500) or Cyanin 5-conjugated donkey anti-rat secondary antibody (Jackson ImmunoResearch Laboratories) (1:500). Samples were mounted using Mowiol 4-88 mounting medium and observed using either a Leica DM4000 B LED epifluorescence microscope (Leica Microsystems, Inc.) for quantitative analysis or a Leica TCS SP8 confocal microscope (Leica Microsystems, Inc.) for confocal image acquisition. Representative confocal micrographs were acquired as 1,024-by-1,024-pixel images using a 63ϫ/1.4 numerical aperture (NA) HC PL APO objective and assembled using Adobe Photoshop CS6.
aBCV formation and reinfection assays. To measure aBCV formation and reinfection events at 72 h pi (12) , BMMs were cultured and infected as specified above, except that gentamicin (20 g/ml) was added between 24 h and 72 h pi for quantification of aBCV formation or was added between 24 and 48 h pi and then removed to measure bacterial reinfection between 48 and 72 h pi. aBCV formation was measured by scoring the percentage of infected cells containing large LAMP1-positive bacterial vacuoles, as described previously (12) . To quantify reinfection events, a secondary, uninfected population of BMMs was loaded with 2 mM Cell Tracker Green CMFDA (5-chloromethylfluorescein diacetate) (Life Technologies, Inc.) for 30 min at 37°C, washed three times with PBS,
